Comparative Pharmacology
Head-to-head clinical analysis: GABAPENTIN ENCARBIL versus LAMICTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABAPENTIN ENCARBIL versus LAMICTAL.
GABAPENTIN ENCARBIL vs LAMICTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gabapentin encarbil is a prodrug of gabapentin, which binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx and inhibiting neurotransmitter release.
Lamotrigine is a triazine antiepileptic drug that inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and modulating presynaptic transmitter release of excitatory amino acids like glutamate and aspartate.
Oral gabapentin encarbil 600 mg once daily with evening meal, titrated based on response and tolerability, maximum 1200 mg once daily. Alternatively, 600 mg twice daily may be used; maximum 2400 mg/day.
Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 1 week, then 150 mg twice daily or 200 mg twice daily (if taking valproate, reduced regimen).
None Documented
None Documented
The terminal elimination half-life of gabapentin derived from gabapentin encarbil is approximately 5-7 hours in patients with normal renal function. This half-life is prolonged in patients with renal impairment (up to 132 hours in anuria). Clinically, steady-state concentrations are achieved within 1-2 days. Twice-daily dosing is effective due to sustained exposure from the prodrug formulation.
14 hours (monotherapy); 7 hours (with enzyme-inducers); 30 hours (with valproate).
Renal: Gabapentin encarbil is a prodrug of gabapentin. Following absorption, it is rapidly hydrolyzed to gabapentin. Gabapentin is primarily excreted unchanged in urine via glomerular filtration. Approximately 80-90% of a dose is recovered in urine as gabapentin, with the remainder as metabolites and minor amounts (≤1%) in feces. Biliary excretion is negligible.
Renal (70% as glucuronide metabolites, 2% as unchanged drug); fecal (2%); biliary (minor).
Category A/B
Category C
Anticonvulsant
Anticonvulsant